glp-1 receptor agonist blue cross blue shield to stop covering popular weight-loss drugs Current Insights, Advantages and Challenges

& Yiu, W

doi: 10.1016/j.yfrne.2016.07.002 83 AkimotoHNegishiAOshimaSWakiyamaHOkitaMHoriiNet al

Interestingly, higher incidence of diabetic retinopathy (DR) complications was noted in patients taking semaglutide (3.0%) compared to placebo (1.5%) in clinical trials, with greater risk in those with a history of DR [32]

While enteral administration offers several advantages over other routes of drug delivery in terms of convenience, promoting medication compliance, it faces several obstacles, of which the most widely recognized are inefficient absorption owing to physical barriers and an acidic microenvironment, along with degradation by proteases and the first-pass metabolism in the liver

Implications Type 2 diabetes mellitus (T2DM): In T2DM, responsiveness to GIP is often impaired